Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma

The EMBO Journal
Götz HartlebenCornelis F Calkhoven

Abstract

The tuberous sclerosis complex (TSC) 1/2 is a negative regulator of the nutrient-sensing kinase mechanistic target of rapamycin complex (mTORC1), and its function is generally associated with tumor suppression. Nevertheless, biallelic loss of function of TSC1 or TSC2 is rarely found in malignant tumors. Here, we show that TSC1/2 is highly expressed in Burkitt's lymphoma cell lines and patient samples of human Burkitt's lymphoma, a prototypical MYC-driven cancer. Mechanistically, we show that MYC induces TSC1 expression by transcriptional activation of the TSC1 promoter and repression of miR-15a. TSC1 knockdown results in elevated mTORC1-dependent mitochondrial respiration enhanced ROS production and apoptosis. Moreover, TSC1 deficiency attenuates tumor growth in a xenograft mouse model. Our study reveals a novel role for TSC1 in securing homeostasis between MYC and mTORC1 that is required for cell survival and tumor maintenance in Burkitt's lymphoma. The study identifies TSC1/2 inhibition and/or mTORC1 hyperactivation as a novel therapeutic strategy for MYC-driven cancers.

References

Mar 15, 1997·Genes & Development·S G KennedyN Hay
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·N N AhmedP N Tsichlis
Feb 21, 1998·Nucleic Acids Research·T HeinemeyerN A Kolchanov
Aug 24, 2000·International Journal of Cancer. Journal International Du Cancer·A PajicD Eick
Jun 18, 2002·Journal of Neurochemistry·Anne-Marie DucheminMaria Hadjiconstantinou
Jul 14, 2004·The Journal of Cell Biology·Laura S HarringtonRichard F Lamb
Nov 10, 2004·The Journal of Cell Biology·Brendan D Manning
Jul 1, 2005·Molecular and Cellular Biology·Feng LiChi V Dang
Nov 2, 2006·Genome Biology·Anne E CarpenterDavid M Sabatini
Dec 11, 2007·Nature Genetics·Tsung-Cheng ChangJoshua T Mendell
Apr 10, 2008·Human Molecular Genetics·Louis S PymarMargaret A Knowles
Jul 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·John R MillsJerry Pelletier
Mar 25, 2010·British Journal of Haematology·Jan-Lukas RobertusAnke van den Berg
Jul 8, 2010·Trends in Molecular Medicine·Virginie Mieulet, Richard F Lamb
Jul 31, 2010·Molecular Cell·Katrin DüvelBrendan D Manning
Dec 16, 2010·Nature Reviews. Molecular Cell Biology·Roberto ZoncuDavid M Sabatini
Aug 31, 2011·Proceedings of the National Academy of Sciences of the United States of America·Nina IlicThomas M Roberts
Sep 29, 2011·Nature Chemical Biology·Markus K MuellnerSebastian M B Nijman
Oct 4, 2011·Current Opinion in Cell Biology·Eva Dazert, Michael N Hall
Feb 16, 2012·Lancet·Elizabeth M MolyneuxSimon Bailey
Apr 3, 2012·Cell·Chi V Dang
Jun 27, 2015·EMBO Reports·Laura M ZidekCornelis F Calkhoven

❮ Previous
Next ❯

Citations

Dec 11, 2019·British Journal of Cancer·Vittoria RaimondiVincenzo Ciminale

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
FACS
flow cytometry
transfection
FCS

Software Mentioned

R
TFSEARCH
ImageJ
R Development Core Team
TargetScan
CellProfiler

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.